Clinical Trial: IMPT Versus IMRT for Diffuse Intrinsic Pontine Glioma

U.S., Oct. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07869524) titled 'IMPT Versus IMRT for Diffuse Intrinsic Pontine Glioma' on Aug. 20.

Brief Summary: This is a prospective, open-label, multicenter, phase III randomized controlled trial comparing intensity-modulated proton therapy (IMPT) with intensity-modulated radiation therapy (IMRT) in participants aged 3-18 years with newly diagnosed diffuse intrinsic pontine glioma (DIPG). Eligible participants will be randomly assigned in a 1:1 ratio to the IMPT group or the IMRT group. Both groups will receive concurrent and adjuvant temozolomide and standardized supportive care. The primary endpoint is the 1-year overall survival rate. Secondary endpoints in...